Clinical trials
Acute Leukemia clinical trials
Below are recruiting acute leukemia clinical trials, each written for real people, not researchers. We’re tracking 943 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06420076RecruitingPhase 1/Phase 2
Sequential CAR-T therapy for CD5/CD7 positive T-cell leukemia/lymphoma
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
Beijing, Beijing MunicipalityAges 2–90 - NCT06429449RecruitingPhase 1
Mitoxantrone for venetoclax-resistant AML
This trial tests a re-purposed drug, mitoxantrone, for people whose AML has not responded to or has come back after standard frontline treatment. The goal is to see if this older drug can help overcome resistance to venetoclax.
Aurora, ColoradoAges 18–80 - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Brighton, MichiganAges 60 years+ - NCT03013998RecruitingPhase 1/Phase 2
Biomarker-guided treatment study for older adults with AML
This trial studies whether choosing treatment based on lab test “biomarkers” (specific genetic or blood markers) can help people with acute myeloid leukemia (AML). It focuses on adults who are not good candidates for the most intensive chemotherapy, and it uses different sub-studies for different AML types.
Phoenix, ArizonaAges 18 years+ - NCT07074496RecruitingEarly Phase 1
Combined cell therapy for newly diagnosed Ph+ ALL
This trial tests a new combination treatment using ThisCART19A cells and olverembatinib in adults newly diagnosed with a type of leukemia that has the Philadelphia chromosome. It aims to see if this approach is safe and effective.
Suzhou, JiangsuAges 18 years+ - NCT06082934RecruitingPhase 1/Phase 2
Triple drug combo for newly diagnosed Ph+ ALL
This trial tests a combination of three targeted drugs (olverembatinib, venetoclax, and dexamethasone) for people newly diagnosed with a specific type of leukemia called Ph+ ALL. The goal is to see if this combination can help control the disease without needing traditional chemotherapy.
Xi'an, ShannxiAges 18 years+ - NCT03450512Recruiting
Study of bowel inflammation in adults with AML on intensive treatment
This study looks at how often a serious bowel problem (neutropenic enterocolitis) happens in adults with acute myeloid leukemia (AML) during intensive chemotherapy that lowers infection-fighting cells. The results may help doctors monitor and prevent complications during treatment.
AmiensAges 18 years+ - NCT04746209RecruitingPhase 2
Blinatumomab after transplant for high-risk B-ALL patients
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
Milwaukee, WisconsinAges Up to 25 years - NCT05241093RecruitingPhase 2
HYML-122 plus cytarabine for FLT3-positive relapsed AML
This trial studies HYML-122 together with cytarabine to treat adults with FLT3-positive acute myeloid leukemia (AML) that has come back or did not respond to prior treatment. It may help shrink the leukemia and improve blood-count recovery when standard treatments haven’t worked.
Suzhou, JiangsuAges 18 years+ - NCT05241106RecruitingPhase 2
HYML-122 for FLT3-mutated AML that came back or did not respond
This Phase 2 trial studies HYML-122 in adults with acute myeloid leukemia (AML) that has either come back or did not respond to prior treatment. It targets tumors with an FLT3 mutation and may offer a new treatment option if your AML is resistant or relapsed.
Suzhou, JiangsuAges 18 years+ - NCT05334823RecruitingPhase 2
CAR T-cell treatment for CD19-positive relapsed leukemia in children
This Phase 2 trial tests pCAR-19B, a customized immune-cell treatment for children and teens with CD19-positive B-ALL that has come back or did not respond to standard therapy. If eligible, you would receive the cell infusion after cell collection and testing to make sure the leukemia cells have the right marker.
Beijing, Beijing MunicipalityAges 3–21 - NCT06179524RecruitingPhase 2
CAR-T-19 for CD19-positive B-ALL in children and young adults
This trial tests a new type of immunotherapy called CAR-T-19 for children and young adults up to age 25 whose B-ALL has returned or is not responding to standard treatments. The CAR-T cells are engineered to find and destroy leukemia cells that have the CD19 protein.
TianjinAges Up to 25 years - NCT06213636RecruitingPhase 1/Phase 2
New CAR T cells for resistant B-cell leukemia or lymphoma
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 2–90 - NCT06308588RecruitingPhase 1/Phase 2
Blinatumomab and asciminib for Ph+ ALL
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
The Bronx, New YorkAges 18 years+ - NCT06548230RecruitingPhase 1/Phase 2
Nadunolimab plus azacitidine for MDS and AML
This trial tests a new combination of drugs (nadunolimab plus azacitidine, sometimes with venetoclax) for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has not been treated much or has come back. The goal is to see if this combination can control the disease better.
Houston, TexasAges 18 years+ - NCT06918431RecruitingPhase 2
Erwinia asparaginase with chemo for new ALL or LBL
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
Phoenix, ArizonaAges 18–54 - NCT07254312Recruiting
Venetoclax blood levels and side effects in AML
This trial checks how the amount of venetoclax in your blood relates to side effects after you are in remission from AML. It aims to help doctors find the safest dose for you.
Pavia, PaviaAges Any age - NCT00501826RecruitingPhase 2
Check nelarabine plus chemotherapy for T-cell blood cancers
This trial tests a combination of chemotherapy with nelarabine in people with T-cell acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma. It may help by improving remission in newly diagnosed or certain previously treated patients whose disease did not respond after one initial treatment.
Houston, TexasAges Any age - NCT07651176Enrolling by invitationPhase 2/Phase 3
Comparing three chemotherapy approaches for newly diagnosed AML
This study tests three different chemotherapy regimens (LDA, LHAA, and DA) in adults aged 18–65 with newly diagnosed acute myeloid leukemia (AML, a blood cancer). The goal is to find which approach works best and is safest for patients fit enough for intensive treatment.
Hangzhou, ZhejiangAges 18–65 - NCT07651163Enrolling by invitationPhase 2/Phase 3
Comparing three chemotherapy regimens for newly diagnosed blood cancer
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
Hangzhou, ZhejiangAges 15–65 - NCT03666000RecruitingPhase 1
Testing a CD19 CAR T cell treatment for relapsed blood cancers
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
Gilbert, ArizonaAges 18 years+ - NCT03852407RecruitingPhase 2
Two kinds of conditioning before matched stem cell transplant
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
AntwerpAges 18–75 - NCT06697600Recruiting
Supporting decisions for older adults with AML and their caregivers
This study helps older adults with newly diagnosed acute myeloid leukemia (AML) and their caregivers make informed decisions about treatment. You and a caregiver (like a family member or friend) will get extra support to talk through your options.
Birmingham, AlabamaAges 60 years+
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute leukemia?
- Yes. Clin2 currently lists 943 recruiting acute leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.